Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Humoral response to vaccination on day 21 in RA patients treated with rituximab

From: Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment

  Controls
n = 10
Pre-RTX
n = 8
Post-RTX
n = 11
Influenza vaccine, % increase    
IgM, median (95% CI) responder, n 104 (96-130) 3 120 (98-139) 6 105 (88-132) 4
IgG, median (95% CI) responder, n 115 (96-191) 6 143 (72-176) 5 109 (85-139)a 5
κ-Light chain median (95% CI) 110 (101-145)a 126 (98-163) 105 (93-124)
λ-Light chain median (95% CI) 126 (98-175)a 147 (94-154)a 113 (93-199)a
Pneumococci vaccine    
IgM, median (95% CI) responder, n 148 (92-541)a 8 107 (93-198) 3 105 (77-322) 5
IgG, median (95% CI) responder, n 126 (71-213)a 7 178 (102-335)a 6 107 (88-151)b 4
κ-Light chain median (95% CI) 154 (85/218)a 124 (97-211)a 105 (94-171)
λ-Light chain median (95% CI) 164 (98/571)a 227 (111-308)a 138 (88-330)a
  1. Pre-RTX group, RA patients treated with RTX 6 days after vaccination; Post-RTX group, RA patients treated with RTX 6 months before vaccination; Controls, RA patients never treated with RTX. The levels of vaccine-specific antibodies at day 0 were taken as 100%. On day 21, the mean increase of antibody levels in the control group was 110%. This value indicated the cutoff for vaccination response in the RTX-treated patients. CI, Confidence interval.
  2. aIncrease of Ig levels on day 21 compared with day 0, P < 0.05.
  3. bIncrease of Ig levels in post-RTX group was lower as compared with pre-RTX group, P < 0.027.